Quoin Pharmaceuticals, Ltd.
QNRX
$6.69
$0.09141.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.38% | -2.95% | -6.10% | -10.15% | -7.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.60% | 1.02% | -5.41% | -8.08% | 1.31% |
| Operating Income | -1.60% | -1.02% | 5.41% | 8.08% | -1.31% |
| Income Before Tax | -3.18% | -0.73% | 15.02% | 18.36% | 7.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.18% | -0.73% | 15.02% | 18.36% | 7.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18% | -0.73% | 15.02% | 18.36% | 7.41% |
| EBIT | -1.60% | -1.02% | 5.41% | 8.08% | -1.31% |
| EBITDA | -1.66% | -1.07% | 5.44% | 8.15% | -1.32% |
| EPS Basic | 77.40% | 69.23% | 50.55% | 19.58% | -10.28% |
| Normalized Basic EPS | 77.40% | 69.23% | 50.55% | 19.58% | -106.86% |
| EPS Diluted | 77.34% | 69.19% | 50.54% | 19.57% | -10.29% |
| Normalized Diluted EPS | 77.40% | 69.23% | 50.55% | 19.58% | -106.86% |
| Average Basic Shares Outstanding | 421.01% | 337.75% | 350.43% | 387.21% | 793.91% |
| Average Diluted Shares Outstanding | 424.14% | 345.83% | 362.50% | 412.50% | 163.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |